MICHAEL W BONNEY
CIK 1219016 · Executive Chair · last filed 2026-07-01
MICHAEL W BONNEY is an Executive Chair who has filed 149 SEC Form 4 insider transactions across 17 companies since 2007. The most recent filing, for AUTL, was dated Jul 1, 2026. Across all open-market trades the lifetime net is −$39.8M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.7M across reported positions. 58 SEC filings were submitted jointly with CUBIST PHARMACEUTICALS INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.67M
17
149
-$39.82M
Filer Profile
HENRI A. TERMEER SQUARE
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AUTL | Director | — | $1.85 | — | $0 | 1 | 2026-07-01 |
| IMUX | Director | — | $9.35 | — | $0 | 1 | 2026-06-29 |
| ALNY | Director | 20,804 | $255.96 | $5.32M | -$14.89M | 18 | 2025-08-19 |
| BMY | Director | 14,501 | $62.86 | $911.5K | $5.2K | 16 | 2021-07-01 |
| Kaleido Biosciences, Inc. (KLDO) Delisted | Executive Chair | 1,233,523 | $0.29 | $357.7K | $999.5K | 3 | 2021-07-01 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Director | 13,459 | $11.19 | $150.7K | $0 | 4 | 2021-06-03 |
| SRPT | Director | 9,126 | $18.67 | $170.4K | $173.5K | 5 | 2020-02-28 |
| CELGENE CORP /DE/ (CELGZ) Delisted | Director | 0 | — | — | $206.0K | 8 | 2019-11-22 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Director | — | $0.00 | — | $0 | 2 | 2019-06-12 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | Director | — | $68.49 | — | $0 | 2 | 2016-06-17 |
| THW | Director | 10,917 | $13.23 | $144.4K | $200.3K | 1 | 2015-08-18 |
| NPS PHARMACEUTICALS INC (NPSP) Delisted | Director | 0 | — | — | -$46.5K | 40 | 2015-02-24 |
| CUBIST PHARMACEUTICALS INC (CBST.Z) Delisted | Chief Executive Officer | 0 | — | — | -$8.36M | 5 | 2015-01-21 |
| THQ | Director | 5,000 | $18.67 | $93.4K | $100.0K | 1 | 2014-07-29 |
| CUBIST PHARMACEUTICALS INC (CBST) Delisted | Chief Executive Officer | 168,700 | — | — | -$18.23M | 37 | 2013-07-02 |
| HQL | Director | 800 | $18.97 | $15.2K | $10.6K | 1 | 2012-03-12 |
| HQH | Director | 665 | $21.24 | $14.1K | $10.3K | 1 | 2012-03-12 |
Recent Filings
149 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-01 | AUTL | Grant (A) | — | $0 | EDGAR |
| 2026-06-29 | IMUX | Grant (A) | — | $0 | EDGAR |
| 2025-08-19 | ALNY | Mixed | — | -$4.27M | EDGAR |
| 2025-08-18 | ALNY | Notice (144) | −11,250 | -$5.06M | EDGAR |
| 2025-05-19 | ALNY | Mixed | — | -$1.65M | EDGAR |
| 2025-05-15 | ALNY | Notice (144) | −11,250 | -$3.03M | EDGAR |
| 2025-05-12 | ALNY | Grant (A) | +775 | $0 | EDGAR |
| 2024-05-20 | ALNY | Grant (A) | — | $0 | EDGAR |
| 2023-12-29 | ALNY | Mixed | — | -$2.96M | EDGAR |
| 2023-12-27 | ALNY | Notice (144) | −30,000 | -$5.74M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.